Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siltuximab + docetaxel
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination of **siltuximab**, a chimeric monoclonal antibody targeting interleukin-6 (IL-6), and **docetaxel**, a small-molecule antineoplastic in the taxane class. Siltuximab binds to IL-6, preventing its interaction with both soluble and membrane-bound IL-6 receptors, thus inhibiting IL-6-mediated signaling. Docetaxel stabilizes microtubules, inhibiting cell division and leading to cancer cell apoptosis. This combination has been explored in clinical studies for **castration-resistant prostate cancer (CRPC)**, showing safety, pharmacokinetic compatibility, and evidence of preliminary efficacy such as PSA declines and partial radiographic responses, though toxicity, especially myelosuppression, is notable. Both agents are approved as single agents for other indications, but this specific combination is **investigational**[1][2][3].
- Other names
- siltuximab + docetaxel
02
Targets
IL-6 (Interleukin 6)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on siltuximab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siltuximab + docetaxel.